AstraZeneca’s mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.
AZ on Wednesday announced the completion of its Alexion acquisition, a week after securing a pivotal nod from the UK’s Competition and Markets Authority (CMA).
Industry watchers were concerned that the deal, the largest announced among pharma players last year, could become a target for an emboldened, Democrat-led Federal Trade Commission (FTC). But those fears were eventually wiped away as AZ secured blessings from the U.S. in April, then from the EU in early July.
The now-completed buyout stands as a key stepping stone for AstraZeneca as it targets an ambitious sales goal of $40 billion in just four years, up from the roughly $26 billion it made in 2020.
With the deal’s closing will come an immediate $6 billion bump to AstraZeneca’s top line as the drugmaker secures two of Alexion’s blockbuster C5 inhibitor franchises, Soliris and Ultomiris.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI